How Universities Became the Engine of the Biotech Industry

Before 1980, groundbreaking discoveries made in university labs with federal funding often collected dust. Intellectual property rights were unclear, and a culture that treated commercialization as beneath the dignity of academic science kept most breakthroughs locked inside the institutions that produced them. Researchers published papers, but the path from a promising finding to a product that could help people remained, for the most part, someone else's problem, and often no one's.

The Bayh-Dole Act of 1980 changed that. Formally known as the Patent and Trademark Law Amendments Act, the law allowed universities to retain ownership of inventions produced through federally funded research and to license those inventions to the private sector. More than 300 new drugs and vaccines trace origins to the system it created. But the legislation did more than unlock a handful of blockbuster therapies. It triggered a complete transformation in how universities think about their role in the innovation economy, giving rise to technology transfer offices (TTOs), university-born startups, new forms of industry partnership and a multibillion-dollar licensing ecosystem that now underpins much of American biotech. Today, that ecosystem faces serious questions about whether it can survive a shifting political and funding landscape.

"Before the Bayh-Dole Act, technology just sat on shelves at research labs," said Stephen Ezell, Vice President of Global Innovation Policy at the Information Technology and Innovation Foundation (ITIF). "By creating certainty around intellectual property rights, the act was crucial in incentivizing a pathway for discoveries to come out of university labs and get commercialized in the private sector."

The law itself was just the starting point. What followed was decades of institution-building as universities invested in TTOs to manage the flow of discoveries from the lab to the marketplace. In the process, those institutions developed an entirely new professional infrastructure, one that has reshaped how science is funded, how startups are born, and how the life sciences industry sources its most promising ideas.

From Transactions to Partnerships

As universities built out their commercialization infrastructure, the nature of their relationships with industry evolved in parallel. What began as simple, one-off licensing deals has given way to something more strategic and sustained.

"The relationship has matured from primarily transactional to more strategic, with an emphasis on long-term, people-centered collaborations," said Shivali Gulab, PhD, Associate Director of Licensing and Business Development at Albert Einstein College of Medicine. "Industry partners are increasingly seeking ongoing access to academic expertise, technology platforms, and clinical insight."

Rather than shopping for a single molecule to license, companies today engage with universities to maintain a continuous scientific dialogue. From the academic side, there is growing recognition that industry brings not just capital but also regulatory expertise, development experience, and the ability to scale.

New players have also entered the equation. Large pharmaceutical companies have launched their own venture arms, entities like Lilly Ventures, that invest directly in early-stage academic technologies. Philanthropic foundations have stepped up as well, funding translational research and, in many cases, reinvesting revenue from successful programs.

Even the mechanics of dealmaking have matured. In the early days, every agreement involved protracted negotiations over basic terms. After decades of benchmarking, universities and companies broadly agree on deal structures, even if they still haggle over financial terms.

Inside the Tech Transfer Office

Behind those evolving partnerships is a profession that has undergone its own transformation. Robin Rasor, Associate Vice President at Duke University’s Translation and Commercialization Office, has spent more than 30 years in tech transfer and has watched it grow from a niche function into a cornerstone of the university mission.

When Rasor started her career, tech transfer barely existed as a profession. Offices were small, often staffed by former industry professionals who had limited knowledge of patents. The community was tight-knit, and practitioners learned on the fly, leaning on a handful of pioneering institutions like Stanford and MIT for guidance.

"In the early days, very few universities took equity in startups. Very few did startups at all," Rasor said. "Most of our licensees were large companies. The faculty weren't trained in entrepreneurship, and didn't have peers who had done it."

That has changed dramatically. Today, graduate students launch companies before finishing their degrees. Faculty participate in an environment where entrepreneurship is normal. Universities have built dedicated teams to help inventors find advisors, secure funding and navigate the startup process, and support structures that did not exist even 10 to 15 years ago at many institutions.

The scope of what TTOs handle has also expanded well beyond patents. Data licensing, content licensing and agreements around artificial intelligence tools, especially those that require access to patient data from university health systems, now represent a growing share of the work.

"We're not the patent office anymore," Rasor said. "We handle many different things, and those kinds of agreements look very different."

What No Other Country Has

The infrastructure that tech transfer offices, venture investors, federal funders, and industry partners have built together is not easily replicated. What makes the American system distinctive is not any single element but the way those pieces interlock to form a self-reinforcing cycle.

Venture capital plays a critical role in that cycle, identifying and funding the kind of frontier innovation that emerges from universities. A recent study out of University of Southern California, published in the The Journal of Financial Economics, found that university innovation draws venture capital to university areas and related industries, where those investors fund high-growth startups pushing the scientific frontier. The result is a clustering effect that compounds over time, concentrating talent, capital, and discovery in the same regions.

Other countries are trying to build something similar, but the approaches look very different. China has invested billions in centralized research parks that co-locate universities, startups, and manufacturing on a single campus, a top-down strategy designed to engineer the kind of clustering that developed organically in the United States. Europe, by contrast, has struggled to integrate universities into its innovation systems at all.

"What makes the U.S. innovation system different from other countries is that we have turned our universities into industries of innovation," said Ezell said. "That's something that no other country has been able to replicate."

The Valley of Death Remains

For all of its strengths, the American system still has a persistent weak point: the gap between an academic discovery and a product that is ready for investment. Most university inventions are at a very early stage. A researcher might identify a promising target but lack the compound, the animal data, or the safety profile needed to attract a partner. Federal funding has traditionally supported basic research, not the translational work required to bridge that gap. The result is what the industry calls the valley of death, a stretch where promising science stalls for lack of resources to move it forward.

"The biggest pain point right now is access to capital," Gulab said. "Early-stage assets are increasingly expected to be de-risked within academia. As a result, academic labs and technology transfer offices are often taking on responsibilities that once sat with early-stage biotech."

Those responsibilities include securing translational funding, conducting animal safety and toxicology studies, and even progressing to investigator-initiated clinical trials, work that, a generation ago, would have been handled by a startup or a corporate partner after licensing.

Universities have responded by creating proof-of-concept funds, incubator spaces and translational core facilities. Philanthropic foundations have also played a growing role, funding translational research and reinvesting revenue from successful programs back into early-stage work. And large pharmaceutical companies have stepped in through their own venture arms, taking on risk at earlier stages than in years past. But in today's tighter funding environment, even these combined resources are under pressure.

"There's a lot of good inventions that don't go anywhere because there's no funding to move them forward," Rasor said.

A System Under Threat

The valley of death is a long-standing challenge. What is newer, and potentially more destabilizing, is a set of political and policy pressures that threaten the public investments the entire system depends on.

The math is straightforward. According to the Association of University Technology Managers, approximately $4.2 million in federal research funding produces one university invention disclosure. Without that upstream investment, the downstream pipeline dries up.

Several recent proposals have converged in ways that could undermine the system simultaneously. The first Trump administration budget of its new term proposed cutting the National Institutes of Health (NIH) budget by 55 percent. Commerce Secretary Howard Lutnick floated the idea of the federal government claiming 50 percent of university patent licensing revenues. Each proposal, if enacted, would remove a different support from the infrastructure that moves discoveries out of the lab.

The concern extends beyond any single policy. No individual cut may seem fatal on its own, but taken together, the cumulative effect threatens to hollow out the ecosystem that has made the United States the global leader in biotech, particularly as competitors invest billions to build their own university-to-market pipelines.

Looking Ahead

The landscape continues to evolve. Academic medical centers are integrating basic science, advanced analytics and patient care in ways that industry alone cannot, positioning them as hubs for the next wave of personalized medicine.

"Advances in AI, molecular profiling, and genetic engineering, are enabling treatments to be tailored to an individual's genetic makeup and lifestyle," Gulab said. "Academic medical centers are evolving beyond being sources of individual inventions."

How success is measured is shifting as well. Gulab noted that tech transfer may increasingly be judged not by invention disclosures or deal counts but by whether discoveries make it into clinical trials, inform patient care and ultimately improve outcomes.

The system that Bayh-Dole set in motion 45 years ago turned universities into launchpads for an industry that did not yet exist, built a profession around moving science into the market and created a model that the rest of the world is still trying to replicate. Whether that system remains productive depends on whether the people who fund it, regulate it and shape its future recognize what it took to build.

"The most common misconception is that technology transfer is about selling science," Gulab said. "In reality, it is about responsibly guiding discoveries from the lab toward development and patient impact. You cannot negotiate your way around experimental reality."